TREA

79316062 - HITMAB

Follow

Information

  • Trademark
  • 79316062
  • Serial Number
    79316062
  • Registration Number
    6854569
  • Filing Date
    April 26, 2021
    3 years ago
  • Registration Date
    September 27, 2022
    2 years ago
  • Transaction Date
    September 22, 2023
    a year ago
  • Status Date
    September 27, 2022
    2 years ago
  • Published for Opposition Date
    July 12, 2022
    2 years ago
  • Location Date
    September 27, 2022
    2 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    HUSSAIN, TASNEEM
  • Attorney Docket Number
    ZW552-22001
    Attorney Name
    Scot A. Duvall
    Law Office Assigned Location Code
    M90
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
HITMAB
Case File Statements
  • GS0051: Vaccines; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; pharmaceutical preparations for the prevention and treatment of HIV/AIDS; pharmaceutical preparations for the prevention and treatment of liver diseases; pharmaceutical preparations for the prevention and treatment of respiratory system disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases, diabetes; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; drugs for medical purposes for the prevention and treatment of HIV/AIDS; drugs for medical purposes for the prevention and treatment of liver diseases; drugs for medical purposes for the prevention and treatment of respiratory system disorders; drugs for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; drugs for medical purposes for the prevention and treatment of gastro-intestinal diseases; drugs for medical purposes for the prevention and treatment of immune system related diseases and disorders; drugs for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; biological preparations for medical purposes for the prevention and treatment of HIV/AIDS; biological preparations for medical purposes for the prevention and treatment of liver diseases; biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; biological preparations for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; medicines for human purposes for the prevention and treatment of HIV/ AIDS; medicines for human purposes for the prevention and treatment of liver diseases; medicines for human purposes for the prevention and treatment of respiratory system disorders; medicines for human purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; medicines for human purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; chemico-pharmaceutical preparations for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation; chemical preparations for pharmaceutical purposes for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation
  • GS0351: Retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies
  • GS0421: Biological research; research and development of new products for others; scientific laboratory services; scientific research; chemical analysis; conducting clinical trials for others; technological research in the fields of medicine, the prevention, treatment and management of illness, health care delivery; technological research in the fields of genetics, genetic engineering, molecular biology and cellular immunology; conducting technical scientific feasibility project studies; chemistry services, namely, consultation, research and advice; chemical research
Case File Event Statements
  • 9/22/2023 - a year ago
    32 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 2/7/2023 - a year ago
    31 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 1/18/2023 - 2 years ago
    30 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 1/18/2023 - 2 years ago
    29 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 12/27/2022 - 2 years ago
    28 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 9/27/2022 - 2 years ago
    27 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 9/27/2022 - 2 years ago
    26 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 7/18/2022 - 2 years ago
    25 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 7/12/2022 - 2 years ago
    24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 7/12/2022 - 2 years ago
    23 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 6/29/2022 - 2 years ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 6/29/2022 - 2 years ago
    21 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 6/22/2022 - 2 years ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 6/6/2022 - 2 years ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 6/6/2022 - 2 years ago
    18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 6/6/2022 - 2 years ago
    17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 6/6/2022 - 2 years ago
    16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 6/6/2022 - 2 years ago
    15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 6/3/2022 - 2 years ago
    14 - DATA MODIFICATION COMPLETED Type: DMCC
  • 6/3/2022 - 2 years ago
    13 - ASSIGNED TO LIE Type: ALIE
  • 5/25/2022 - 2 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/24/2022 - 2 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/24/2022 - 2 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/6/2022 - 2 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 1/18/2022 - 3 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 1/18/2022 - 3 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 12/28/2021 - 3 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 12/27/2021 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 12/22/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/27/2021 - 3 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 7/23/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/22/2021 - 3 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR